Previous 10 | Next 10 |
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financi...
Intersect ENT, Inc. (XENT) Q4 2020 Earnings Conference Call March 09, 2021 08:30 AM ET Company Participants Randy Meier - Chief Financial Officer Tom West - President & Chief Executive Officer Conference Call Participants Robbie Marcus - JPMorgan Richard Newitter - SVB Leerink Chris Pasqu...
Intersect ENT (XENT): Q4 Non-GAAP EPS of -$0.54 misses by $0.22; GAAP EPS of -$0.62 misses by $0.31.Revenue of $28.2M (-11.3% Y/Y) beats by $0.37M.Press Release For further details see: Intersect ENT EPS misses by $0.22, beats on revenue
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Overview ...
Intersect ENT (NASDAQ:XENT) is scheduled to announce Q4 earnings results on Tuesday, March 9th, before market open.The consensus EPS Estimate is -$0.32 (-28.0% Y/Y) and the consensus Revenue Estimate is $27.83M (-12.3% Y/Y).Over the last 1 year, XENT has beaten EPS estimates 75% of the time a...
[[CMD]], [[DKS]], [[PLCE]], [[PQG]], [[THO]], [[XENT]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
Pass-Through Status Will Continue Under the New Code Through June 30, 2023 Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Med...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release fourth quarter and full year 2020 financial results on Tuesday, March 9, 2021. The Company expec...
Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financi...
News, Short Squeeze, Breakout and More Instantly...
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including a...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third qu...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to...